Morphocell Technologies is a Montreal-based regenerative medicine company dedicated to developing innovative therapies for severe liver diseases. Central to their mission is the ReLiver technology, which involves the creation of engineered liver tissue derived from pluripotent stem cells. This unique approach aims to provide effective treatments for acute and acute-on-chronic liver failure by utilizing allogeneic cell therapy products that can replicate mature liver functions. The company is focused on transforming the treatment landscape for liver disease through advanced tissue engineering and has a robust pipeline that may extend to other organ deficiencies in the future.

The leadership team at Morphocell Technologies includes experts in cell and gene therapy, such as Dr. Calley Hirsch, who brings extensive experience in preclinical development. The company emphasizes a culture of innovation and technical excellence, aiming to translate groundbreaking research into real-world solutions for patients. With a commitment to improving patient outcomes, Morphocell is actively raising funds to support its development efforts and expand its therapeutic platform, positioning itself at the forefront of regenerative medicine.

Canada

Morphocell Technologies Inc. is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues targeting liver failure. The Company is a spin-off of the Hepatology and Cell Therapy lab of Sainte-Justine University Hospital Center, in Montreal. Founded in April 2018 on the technology developed by Dr.Paganelli, a pediatric transplant hepatologist and stem cell scientist, Morphocell Technologies aims at bringing to market the first effective treatment for acute, chronic and acute-on-chronic liver failure.

Morphocell Technologies

Company Details